Jason Lewis

List of Publications by Year in Descending Order

325 papers	18,181 citations	74 h-index	120 g-index
348 ext. papers	20,872 ext. citations	7.6 avg, IF	6.69 L-index

#	Paper	IF	Citations
325	Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer exhibits antitumor efficacy with low toxicity.. *Clinical Cancer Research*, **2022**,	12.9	0
324	EGFR-Targeted ImmunoPET of UMUC3 Orthotopic Bladder Tumors.. *Molecular Imaging and Biology*, **2022**, 1	3.8	1
323	Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer.. *Nature Communications*, **2022**, 13, 2526	17.4	1
322	Novel Positron-Emitting Radiopharmaceuticals **2022**, 1-48		
321	A Systematic Evaluation of Antibody Modification and Zr-Radiolabeling for Optimized Immuno-PET. *Bioconjugate Chemistry*, **2021**, 32, 1177-1191	6.3	6
320	Predicting CAR-T cell Immunotherapy Success through ImmunoPET. *Clinical Cancer Research*, **2021**, 27, 911-912	12.9	2
319	"Friction by Definition": Conflict at Patient Handover Between Emergency and Internal Medicine Physicians at an Academic Medical Center. *Western Journal of Emergency Medicine*, **2021**, 22, 1227-1239	3.3	0
318	Exploiting the MUC5AC Antigen for Noninvasive Identification of Pancreatic Cancer. *Journal of Nuclear Medicine*, **2021**, 62, 1384-1390	8.9	0
317	Technical Note: Patient-morphed mesh-type phantoms to support personalized nuclear medicine dosimetry - a proof of concept study. *Medical Physics*, **2021**, 48, 2018-2026	4.4	0
316	Applications of nuclear-based imaging in gene and cell therapy: probe considerations. *Molecular Therapy - Oncolytics*, **2021**, 20, 447-458	6.4	3
315	Reply: Potential Use of Radiolabeled Antibodies for Imaging and Treatment of COVID-19. *Journal of Nuclear Medicine*, **2021**, 62, 1020-1021	8.9	
314	Synthesis and Comparative Evaluation of Site-Specifically Labeled Radioimmunoconjugates for DLL3-Targeted ImmunoPET. *Bioconjugate Chemistry*, **2021**, 32, 1255-1262	6.3	0
313	Medical imaging and nuclear medicine: a Lancet Oncology Commission. *Lancet Oncology, The*, **2021**, 22, e136-e172	21.7	39
312	Recent Advances in Radiometals for Combined Imaging and Therapy in Cancer. *ChemMedChem*, **2021**, 16, 2909-2941	3.7	13
311	Tim-4 cavity-resident macrophages impair anti-tumor CD8 T cell immunity. *Cancer Cell*, **2021**, 39, 973-988.e9	23	13
310	Imaging Early-Stage Metastases Using an F-Labeled VEGFR-1-Specific Single Chain VEGF Mutant. *Molecular Imaging and Biology*, **2021**, 23, 340-349	3.8	1
309	Immuno-PET Detects Changes in Multi-RTK Tumor Cell Expression Levels in Response to Targeted Kinase Inhibition. *Journal of Nuclear Medicine*, **2021**, 62, 366-371	8.9	2

308	Head-to-Head Evaluation of F-FES and F-FDG PET/CT in Metastatic Invasive Lobular Breast Cancer. *Journal of Nuclear Medicine*, **2021**, 62, 326-331	8.9	15
307	ImmunoPET Imaging of Pancreatic Tumors with Zr-Labeled Gold Nanoparticle-Antibody Conjugates. *Molecular Imaging and Biology*, **2021**, 23, 84-94	3.8	5
306	Antibody-Based Molecular Imaging **2021**, 547-562		
305	A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. *European Journal of Nuclear Medicine and Molecular Imaging*, **2021**, 48, 2642-2651	8.8	14
304	Imaging Tumor-Infiltrating Lymphocytes in Brain Tumors with [Cu]Cu-NOTA-anti-CD8 PET. *Clinical Cancer Research*, **2021**, 27, 1958-1966	12.9	8
303	Bimodal Imaging of Mouse Peripheral Nerves with Chlorin Tracers. *Molecular Pharmaceutics*, **2021**, 18, 940-951	5.6	0
302	Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system. *Nature Communications*, **2021**, 12, 4669	17.4	5
301	ERK Inhibition Improves Anti-PD-L1 Immune Checkpoint Blockade in Preclinical Pancreatic Ductal Adenocarcinoma. *Molecular Cancer Therapeutics*, **2021**, 20, 2026-2034	6.1	5
300	Imaging of Cancer -Secretase Activity Using an Inhibitor-Based PET Probe. *Clinical Cancer Research*, **2021**, 27, 6145-6155	12.9	2
299	Novel Tracers and Radionuclides in PET Imaging. *Radiologic Clinics of North America*, **2021**, 59, 887-918	2.3	
298	First-in-Human Trial of Epichaperome-Targeted PET in Patients with Cancer. *Clinical Cancer Research*, **2020**, 26, 5178-5187	12.9	8
297	Comparison of Ga-DOTA-JR11 PET/CT with dosimetric Lu-satoreotide tetraxetan (Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. *European Journal of Nuclear Medicine and Molecular Imaging*, **2020**, 47, 3047-3057	8.8	4
296	Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following - and -particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. *Theranostics*, **2020**, 10, 5802-5814	12.1	6
295	Radiopharmacologic screening of antibodies to the unshed ectodomain of MUC16 in ovarian cancer identifies a lead candidate for clinical translation. *Nuclear Medicine and Biology*, **2020**, 86-87, 9-19	2.1	1
294	Identification of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer by Using HER2-targeted Zr-Pertuzumab PET/CT. *Radiology*, **2020**, 296, 370-378	20.5	13
293	Inhibiting cancer metabolism by aromatic carbohydrate amphiphiles that act as antagonists of the glucose transporter GLUT1. *Chemical Science*, **2020**, 11, 3737-3744	9.4	9
292	pH-Responsive Polymers for Improving the Signal-to-Noise Ratio of Hypoxia PET Imaging with [F]Fluoromisonidazole. *Macromolecular Rapid Communications*, **2020**, 41, e2000061	4.8	4
291	First-in-Humans Trial of Dasatinib-Derivative Tracer for Tumor Kinase-Targeted PET. *Journal of Nuclear Medicine*, **2020**, 61, 1580-1587	8.9	3

290	A Molecularly Targeted Intraoperative Near-Infrared Fluorescence Imaging Agent for High-Grade Serous Ovarian Cancer. *Molecular Pharmaceutics*, **2020**, 17, 3140-3147	5.6	3
289	Design and preclinical evaluation of nanostars for the passive pretargeting of tumor tissue. *Nuclear Medicine and Biology*, **2020**, 84-85, 63-72	2.1	11
288	Manipulating the In Vivo Behaviour of Ga with Tris(Hydroxypyridinone) Chelators: Pretargeting and Blood Clearance. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	5
287	Radiotheranostics: a roadmap for future development. *Lancet Oncology, The*, **2020**, 21, e146-e156	21.7	59
286	The Influence of Glycans-Specific Bioconjugation on the FcRI Binding and Performance of Zr-DFO-Pertuzumab. *Theranostics*, **2020**, 10, 1746-1757	12.1	15
285	PET/CT Imaging with an F-Labeled Galactodendritic Unit in a Galectin-1-Overexpressing Orthotopic Bladder Cancer Model. *Journal of Nuclear Medicine*, **2020**, 61, 1369-1375	8.9	3
284	Safety and Feasibility of PARP1/2 Imaging with F-PARPi in Patients with Head and Neck Cancer. *Clinical Cancer Research*, **2020**, 26, 3110-3116	12.9	15
283	Fluorescence labeling of a Na1.7-targeted peptide for near-infrared nerve visualization. *EJNMMI Research*, **2020**, 10, 49	3.6	6
282	Demarcation of Sepsis-Induced Peripheral and Central Acidosis with pH (Low) Insertion Cycle Peptide. *Journal of Nuclear Medicine*, **2020**, 61, 1361-1368	8.9	5
281	The Future of Nuclear Medicine, Molecular Imaging, and Theranostics. *Journal of Nuclear Medicine*, **2020**, 61, 263S-272S	8.9	22
280	3D-Printable Platform for High-Throughput Small-Animal Imaging. *Journal of Nuclear Medicine*, **2020**, 61, 1691-1692	8.9	0
279	Radiopharmaceuticals in Oncology **2020**, 535-570		
278	Delivery of polymeric nanostars for molecular imaging and endoradiotherapy through the enhanced permeability and retention (EPR) effect. *Theranostics*, **2020**, 10, 567-584	12.1	38
277	Multimodality labeling strategies for the investigation of nanocrystalline cellulose biodistribution in a mouse model of breast cancer. *Nuclear Medicine and Biology*, **2020**, 80-81, 1-12	2.1	8
276	ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors. *Theranostics*, **2020**, 10, 151-165	12.1	14
275	HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer. *Molecular Pharmaceutics*, **2020**, 17, 327-337	5.6	11
274	Acute Statin Treatment Improves Antibody Accumulation in EGFR- and PSMA-Expressing Tumors. *Clinical Cancer Research*, **2020**, 26, 6215-6229	12.9	9
273	Antibody-Targeted Imaging of Gastric Cancer. *Molecules*, **2020**, 25,	4.8	3

272	Comparison of Methods for Surface Modification of Barium Titanate Nanoparticles for Aqueous Dispersibility: Toward Biomedical Utilization of Perovskite Oxides. *ACS Applied Materials & Interfaces*, **2020**, 12, 51135-51147	9.5	7
271	Oncology-Inspired Treatment Options for COVID-19. *Journal of Nuclear Medicine*, **2020**, 61, 1720-1723	8.9	11
270	Polyazamacrocycle Ligands Facilitate Zr Radiochemistry and Yield Zr Complexes with Remarkable Stability. *Inorganic Chemistry*, **2020**, 59, 17473-17487	5.1	4
269	A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89. *Inorganic Chemistry*, **2020**, 59, 11715-11727	5.1	9
268	Harnessing Cu/Cu for a theranostic approach to pretargeted radioimmunotherapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 28316-28327	11.5	19
267	pHLIP ICG for delineation of tumors and blood flow during fluorescence-guided surgery. *Scientific Reports*, **2020**, 10, 18356	4.9	5
266	B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study. *Journal of Clinical Oncology*, **2020**, 38, 4283-4291	2.2	19
265	Aromatic carbohydrate amphiphile disrupts cancer spheroids and prevents relapse. *Nanoscale*, **2020**, 12, 19088-19092	7.7	3
264	Leveraging synthetic chlorins for bio-imaging applications. *Chemical Communications*, **2020**, 56, 12608-12611	5.8	2
263	Multimodal Positron Emission Tomography Imaging to Quantify Uptake of Zr-Labeled Liposomes in the Atherosclerotic Vessel Wall. *Bioconjugate Chemistry*, **2020**, 31, 360-368	6.3	12
262	The Impact of Positron Range on PET Resolution, Evaluated with Phantoms and PHITS Monte Carlo Simulations for Conventional and Non-conventional Radionuclides. *Molecular Imaging and Biology*, **2020**, 22, 73-84	3.8	18
261	First-in-Humans Imaging with Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting. *Journal of Nuclear Medicine*, **2020**, 61, 512-519	8.9	86
260	An Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor. *Journal of Nuclear Medicine*, **2020**, 61, 433-436	8.9	14
259	CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging. *Radiology*, **2020**, 295, 606-615	20.5	35
258	iNOS Regulates the Therapeutic Response of Pancreatic Cancer Cells to Radiotherapy. *Cancer Research*, **2020**, 80, 1681-1692	10.1	11
257	Targeted Brain Tumor Radiotherapy Using an Auger Emitter. *Clinical Cancer Research*, **2020**, 26, 2871-2881	12.9	37
256	HER2-Mediated Internalization of Cytotoxic Agents in Amplified or Mutant Lung Cancers. *Cancer Discovery*, **2020**, 10, 674-687	24.4	66
255	Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist Lu-Satoreotide Tetraxetan. *Clinical Cancer Research*, **2019**, 25, 6939-6947	12.9	34

254	Retooling a Blood-Based Biomarker: Phase I Assessment of the High-Affinity CA19-9 Antibody HuMab-5B1 for Immuno-PET Imaging of Pancreatic Cancer. *Clinical Cancer Research*, **2019**, 25, 7014-7023	12.9	25
253	Trastuzumab gold-conjugates: synthetic approach and in vitro evaluation of anticancer activities in breast cancer cell lines. *Chemical Communications*, **2019**, 55, 1394-1397	5.8	11
252	Temporal Modulation of HER2 Membrane Availability Increases Pertuzumab Uptake and Pretargeted Molecular Imaging of Gastric Tumors. *Journal of Nuclear Medicine*, **2019**, 60, 1569-1578	8.9	17
251	A rapid bead-based radioligand binding assay for the determination of target-binding fraction and quality control of radiopharmaceuticals. *Nuclear Medicine and Biology*, **2019**, 71, 32-38	2.1	16
250	Acid specific dark quencher QC1 pHLIP for multi-spectral optoacoustic diagnoses of breast cancer. *Scientific Reports*, **2019**, 9, 8550	4.9	12
249	PARaDIM: A PHITS-Based Monte Carlo Tool for Internal Dosimetry with Tetrahedral Mesh Computational Phantoms. *Journal of Nuclear Medicine*, **2019**, 60, 1802-1811	8.9	9
248	Molecular Imaging Companion Diagnostics **2019**, 201-228		1
247	Toward the Optimization of Click-Mediated Pretargeted Radioimmunotherapy. *Molecular Pharmaceutics*, **2019**, 16, 2259-2263	5.6	13
246	Assessment of Simplified Methods for Quantification of F-FDHT Uptake in Patients with Metastatic Castration-Resistant Prostate Cancer. *Journal of Nuclear Medicine*, **2019**, 60, 1221-1227	8.9	5
245	Biodistribution and Dosimetry of Intraventricularly Administered I-Omburtamab in Patients with Metastatic Leptomeningeal Tumors. *Journal of Nuclear Medicine*, **2019**, 60, 1794-1801	8.9	13
244	Improved synthesis of the bifunctional chelator p-SCN-Bn-HOPO. *Organic and Biomolecular Chemistry*, **2019**, 17, 6866-6871	3.9	6
243	Paradigms for Precision Medicine in Epichaperome Cancer Therapy. *Cancer Cell*, **2019**, 36, 559-573.e7	24.3	25
242	and Amplifications Determine Response to HER2 Inhibition in -Amplified Esophagogastric Cancer. *Cancer Discovery*, **2019**, 9, 199-209	24.4	79
241	Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis. *JACC: Cardiovascular Imaging*, **2019**, 12, 2015-2026	8.4	42
240	Leveraging Bioorthogonal Click Chemistry to Improve Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma. *Clinical Cancer Research*, **2019**, 25, 868-880	12.9	35
239	Biodistribution and radiation dose estimates for Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors. *European Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 46, 677-685	8.8	27
238	Harnessing Androgen Receptor Pathway Activation for Targeted Alpha Particle Radioimmunotherapy of Breast Cancer. *Clinical Cancer Research*, **2019**, 25, 881-891	12.9	13
237	A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer. *Clinical Cancer Research*, **2019**, 25, 166-176	12.9	10

236	Tumor-Specific Zr-89 Immuno-PET Imaging in a Human Bladder Cancer Model. *Molecular Imaging and Biology*, **2018**, 20, 808-815	3.8	18
235	Click-Mediated Pretargeted Radioimmunotherapy of Colorectal Carcinoma. *Molecular Pharmaceutics*, **2018**, 15, 1729-1734	5.6	27
234	Imaging of human epidermal growth factor receptors for patient selection and response monitoring - From PET imaging and beyond. *Cancer Letters*, **2018**, 419, 139-151	9.9	24
233	Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 2. *Journal of Nuclear Medicine*, **2018**, 59, 1020-1027	8.9	47
232	Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. *Nature Communications*, **2018**, 9, 1629	17.4	23
231	Reproducibility and Repeatability of Semiquantitative F-Fluorodihydrotestosterone Uptake Metrics in Castration-Resistant Prostate Cancer Metastases: A Prospective Multicenter Study. *Journal of Nuclear Medicine*, **2018**, 59, 1516-1523	8.9	13
230	In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of F-(2S,4R)-4-Fluoroglutamine. *Radiology*, **2018**, 287, 667-675	20.5	51
229	The inverse electron-demand Diels-Alder reaction as a new methodology for the synthesis of Ac-labelled radioimmunoconjugates. *Chemical Communications*, **2018**, 54, 2599-2602	5.8	26
228	Bioorthogonal Masking of Circulating Antibody-TCO Groups Using Tetrazine-Functionalized Dextran Polymers. *Bioconjugate Chemistry*, **2018**, 29, 538-545	6.3	28
227	Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide therapy-Model, vector, and radionuclide selection. *Journal of Labelled Compounds and Radiopharmaceuticals*, **2018**, 61, 611-635	1.9	16
226	Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models. *Cancer Research*, **2018**, 78, 1820-1832	10.1	48
225	PARP-1-Targeted Radiotherapy in Mouse Models of Glioblastoma. *Journal of Nuclear Medicine*, **2018** , 59, 1225-1233	8.9	28
224	Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies-Part 1. *Journal of Nuclear Medicine*, **2018**, 59, 878-884	8.9	74
223	Pharmacokinetics, Biodistribution, and Radiation Dosimetry for Zr-Trastuzumab in Patients with Esophagogastric Cancer. *Journal of Nuclear Medicine*, **2018**, 59, 161-166	8.9	60
222	Biodistribution and Dosimetry of F-Meta-Fluorobenzylguanidine: A First-in-Human PET/CT Imaging Study of Patients with Neuroendocrine Malignancies. *Journal of Nuclear Medicine*, **2018**, 59, 147-153	8.9	65
221	A phase II study of radioimmunotherapy with intraventricular I-3F8 for medulloblastoma. *Pediatric Blood and Cancer*, **2018**, 65, e26754	3	26
220	Noninvasive Zr-Transferrin PET Shows Improved Tumor Targeting Compared with F-FDG PET in MYC-Overexpressing Human Triple-Negative Breast Cancer. *Journal of Nuclear Medicine*, **2018**, 59, 51-57	8.9	26
219	Long-Half-Life Zr-Labeled Radiotracers Can Guide Percutaneous Biopsy Within the PET/CT Suite Without Reinjection of Radiotracer. *Journal of Nuclear Medicine*, **2018**, 59, 399-402	8.9	8

218	Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. *Lancet Oncology, The*, **2018**, 19, 1040-1050	21.7	138
217	Imaging EGFR and HER3 through Zr-labeled MEHD7945A (Duligotuzumab). *Scientific Reports*, **2018**, 8, 9043	4.9	15
216	First-in-Human Human Epidermal Growth Factor Receptor 2-Targeted Imaging Using Zr-Pertuzumab PET/CT: Dosimetry and Clinical Application in Patients with Breast Cancer. *Journal of Nuclear Medicine*, **2018**, 59, 900-906	8.9	82
215	Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer. *JAMA Oncology*, **2018**, 4, 217-224	13.4	60
214	Leveraging PET to image folate receptor therapy of an antibody-drug conjugate. *EJNMMI Research*, **2018**, 8, 87	3.6	6
213	Caveolin-1 mediates cellular distribution of HER2 and affects trastuzumab binding and therapeutic efficacy. *Nature Communications*, **2018**, 9, 5137	17.4	51
212	Clinical Potential of Human Epidermal Growth Factor Receptor 2 and Human Epidermal Growth Factor Receptor 3 Imaging in Breast Cancer. *PET Clinics*, **2018**, 13, 423-435	2.2	15
211	Establishment of the In Vivo Efficacy of Pretargeted Radioimmunotherapy Utilizing Inverse Electron Demand Diels-Alder Click Chemistry. *Molecular Cancer Therapeutics*, **2017**, 16, 124-133	6.1	63
210	Zr-DFO-AMG102 Immuno-PET to Determine Local Hepatocyte Growth Factor Protein Levels in Tumors for Enhanced Patient Selection. *Journal of Nuclear Medicine*, **2017**, 58, 1386-1394	8.9	24
209	Preloading with Unlabeled CA19.9 Targeted Human Monoclonal Antibody Leads to Improved PET Imaging with Zr-5B1. *Molecular Pharmaceutics*, **2017**, 14, 908-915	5.6	21
208	Applications of pHLIP Technology for Cancer Imaging and Therapy. *Trends in Biotechnology*, **2017**, 35, 653-664	15.1	57
207	Noninvasive Interrogation of DLL3 Expression in Metastatic Small Cell Lung Cancer. *Cancer Research*, **2017**, 77, 3931-3941	10.1	52
206	Antibodies Against Specific MUC16 Glycosylation Sites Inhibit Ovarian Cancer Growth. *ACS Chemical Biology*, **2017**, 12, 2085-2096	4.9	20
205	Human Epidermal Growth Factor Receptor 2-Targeted PET/Single- Photon Emission Computed Tomography Imaging of Breast Cancer: Noninvasive Measurement of a Biomarker Integral to Tumor Treatment and Prognosis. *PET Clinics*, **2017**, 12, 269-288	2.2	36
204	Multinuclear NMR and MRI Reveal an Early Metabolic Response to mTOR Inhibition in Sarcoma. *Cancer Research*, **2017**, 77, 3113-3120	10.1	15
203	Noninvasive Measurement of mTORC1 Signaling with Zr-Transferrin. *Clinical Cancer Research*, **2017**, 23, 3045-3052	12.9	24
202	Current status and future challenges for molecular imaging. *Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences*, **2017**, 375,	3	15
201	Pretargeting of internalizing trastuzumab and cetuximab with a F-tetrazine tracer in xenograft models. *EJNMMI Research*, **2017**, 7, 95	3.6	47

200	Targeted PET imaging strategy to differentiate malignant from inflamed lymph nodes in diffuse large B-cell lymphoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E7441-E7449	11.5	22
199	Multiplexed imaging for diagnosis and therapy. *Nature Biomedical Engineering*, **2017**, 1, 697-713	19	78
198	Exploring Structural Parameters for Pretargeting Radioligand Optimization. *Journal of Medicinal Chemistry*, **2017**, 60, 8201-8217	8.3	37
197	89Zr-Trastuzumab PET/CT for Detection of Human Epidermal Growth Factor Receptor 2-Positive Metastases in Patients With Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. *Clinical Nuclear Medicine*, **2017**, 42, 912-917	1.7	54
196	Prospective Clinical Trial of F-Fluciclovine PET/CT for Determining the Response to Neoadjuvant Therapy in Invasive Ductal and Invasive Lobular Breast Cancers. *Journal of Nuclear Medicine*, **2017**, 58, 1037-1042	8.9	34
195	Imaging biomarker roadmap for cancer studies. *Nature Reviews Clinical Oncology*, **2017**, 14, 169-186	19.4	532
194	Novel Positron-Emitting Radiopharmaceuticals **2017**, 129-171		
193	(18)F-Based Pretargeted PET Imaging Based on Bioorthogonal Diels-Alder Click Chemistry. *Bioconjugate Chemistry*, **2016**, 27, 298-301	6.3	110
192	Pretargeted Immuno-PET of Pancreatic Cancer: Overcoming Circulating Antigen and Internalized Antibody to Reduce Radiation Doses. *Journal of Nuclear Medicine*, **2016**, 57, 453-9	8.9	64
191	Fully automated synthesis of [(18) F]fluoro-dihydrotestosterone ([(18) F]FDHT) using the FlexLab module. *Journal of Labelled Compounds and Radiopharmaceuticals*, **2016**, 59, 424-8	1.9	8
190	First-in-Human Imaging with 89Zr-Df-IAB2M Anti-PSMA Minibody in Patients with Metastatic Prostate Cancer: Pharmacokinetics, Biodistribution, Dosimetry, and Lesion Uptake. *Journal of Nuclear Medicine*, **2016**, 57, 1858-1864	8.9	91
189	PET Imaging of Extracellular pH in Tumors with (64)Cu- and (18)F-Labeled pHLIP Peptides: A Structure-Activity Optimization Study. *Bioconjugate Chemistry*, **2016**, 27, 2014-23	6.3	43
188	A comparative evaluation of the chelators H4octapa and CHX-A?-DTPA with the therapeutic radiometal (90)Y. *Nuclear Medicine and Biology*, **2016**, 43, 566-576	2.1	21
187	Emerging Radiopharmaceuticals in Clinical Oncology **2016**, 1-43		
186	Click Chemistry and Radiochemistry: The First 10 Years. *Bioconjugate Chemistry*, **2016**, 27, 2791-2807	6.3	159
185	Synthesis and evaluation of an (18)F-labeled pyrimidine-pyridine amine for targeting CXCR4 receptors in gliomas. *Nuclear Medicine and Biology*, **2016**, 43, 606-11	2.1	9
184	In Vivo PET Imaging of HDL in Multiple Atherosclerosis Models. *JACC: Cardiovascular Imaging*, **2016**, 9, 950-61	8.4	62
183	Applying Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins. *Molecular Pharmaceutics*, **2016**, 13, 683-8	5.6	11

182	Preclinical 89Zr Immuno-PET of High-Grade Serous Ovarian Cancer and Lymph Node Metastasis. *Journal of Nuclear Medicine*, **2016**, 57, 771-6	8.9	19
181	Initial Results of a Prospective Clinical Trial of 18F-Fluciclovine PET/CT in Newly Diagnosed Invasive Ductal and Invasive Lobular Breast Cancers. *Journal of Nuclear Medicine*, **2016**, 57, 1350-6	8.9	43
180	Novel Positron Emitting Radiopharmaceuticals **2016**, 1-43		
179	A Pretargeted Approach for the Multimodal PET/NIRF Imaging of Colorectal Cancer. *Theranostics*, **2016**, 6, 2267-2277	12.1	42
178	Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate. *Bioconjugate Chemistry*, **2016**, 27, 1789-95	6.3	46
177	Radiosynthesis of the iodine-124 labeled Hsp90 inhibitor PU-H71. *Journal of Labelled Compounds and Radiopharmaceuticals*, **2016**, 59, 129-32	1.9	16
176	Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy. *Nature Communications*, **2016**, 7, 11838	17.4	73
175	Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. *Science Translational Medicine*, **2016**, 8, 367ra167	17.5	15
174	Molecular Imaging of Ovarian Cancer. *Journal of Nuclear Medicine*, **2016**, 57, 827-33	8.9	13
173	Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. *Journal of Nuclear Medicine*, **2016**, 57, 1523-1528	8.9	118
172	The epichaperome is an integrated chaperome network that facilitates tumour survival. *Nature*, **2016**, 538, 397-401	50.4	148
171	Selective Imaging of VEGFR-1 and VEGFR-2 Using 89Zr-Labeled Single-Chain VEGF Mutants. *Journal of Nuclear Medicine*, **2016**, 57, 1811-1816	8.9	20
170	Fully-automated synthesis of 16β(18)F-fluoro-5α-dihydrotestosterone (FDHT) on the ELIXYS radiosynthesizer. *Applied Radiation and Isotopes*, **2015**, 103, 9-14	1.7	8
169	PET Imaging of Tumor-Associated Macrophages with 89Zr-Labeled High-Density Lipoprotein Nanoparticles. *Journal of Nuclear Medicine*, **2015**, 56, 1272-7	8.9	120
168	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. *Science Translational Medicine*, **2015**, 7, 283ra51	17.5	204
167	A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. *Clinical Cancer Research*, **2015**, 21, 5277-85	12.9	129
166	Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. *Cancer Research*, **2015**, 75, 4688-96	10.1	84
165	Optimization of a Pretargeted Strategy for the PET Imaging of Colorectal Carcinoma via the Modulation of Radioligand Pharmacokinetics. *Molecular Pharmaceutics*, **2015**, 12, 3575-87	5.6	73

164	p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET. *Bioconjugate Chemistry*, **2015**, 26, 2579-91	6.3	83
163	Challenges of Pancreatic Cancer. *Cancer Journal (Sudbury, Mass.)*, **2015**, 21, 188-93	2.2	34
162	Glutamine-based PET imaging facilitates enhanced metabolic evaluation of gliomas in vivo. *Science Translational Medicine*, **2015**, 7, 274ra17	17.5	206
161	Harnessing the bioorthogonal inverse electron demand Diels-Alder cycloaddition for pretargeted PET imaging. *Journal of Visualized Experiments*, **2015**, e52335	1.6	6
160	Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy. *Journal of Neuro-Oncology*, **2015**, 123, 245-9	4.8	13
159	Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 15850-5	11.5	71
158	Evaluation of hypoxia with copper-labeled diacetyl-bis(N-methylthiosemicarbazone). *Seminars in Nuclear Medicine*, **2015**, 45, 177-85	5.4	28
157	The bioconjugation and radiosynthesis of 89Zr-DFO-labeled antibodies. *Journal of Visualized Experiments*, **2015**,	1.6	46
156	H6phospa-trastuzumab: bifunctional methylenephosphonate-based chelator with 89Zr, 111In and 177Lu. *Dalton Transactions*, **2014**, 43, 119-31	4.3	49
155	Underscoring the influence of inorganic chemistry on nuclear imaging with radiometals. *Inorganic Chemistry*, **2014**, 53, 1880-99	5.1	68
154	Noninvasive Imaging of PSMA in prostate tumors with (89)Zr-Labeled huJ591 engineered antibody fragments: the faster alternatives. *Molecular Pharmaceutics*, **2014**, 11, 3965-73	5.6	54
153	A modular labeling strategy for in vivo PET and near-infrared fluorescence imaging of nanoparticle tumor targeting. *Journal of Nuclear Medicine*, **2014**, 55, 1706-11	8.9	72
152	Targeting breast tumors with pH (low) insertion peptides. *Molecular Pharmaceutics*, **2014**, 11, 2896-905	5.6	46
151	Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma. *European Journal of Nuclear Medicine and Molecular Imaging*, **2014**, 41, 985-94	8.8	54
150	Alternative chelator for □Zr radiopharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO). *Journal of Medicinal Chemistry*, **2014**, 57, 4849-60	8.3	116
149	Synthesis and evaluation of (18)F-labeled ATP competitive inhibitors of topoisomerase II as probes for imaging topoisomerase II expression. *European Journal of Medicinal Chemistry*, **2014**, 86, 769-81	6.8	8
148	What a difference a carbon makes: H□octapa vs H□3octapa, ligands for In-111 and Lu-177 radiochemistry. *Inorganic Chemistry*, **2014**, 53, 10412-31	5.1	32
147	CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. *Genes and Development*, **2014**, 28, 1800-14	12.6	118

146	A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. *Journal of Urology*, **2014**, 191, 1439-45	2.5	62
145	Influence of free fatty acids on glucose uptake in prostate cancer cells. *Nuclear Medicine and Biology*, **2014**, 41, 254-8	2.1	9
144	Development of a minimal saponin vaccine adjuvant based on QS-21. *Nature Chemistry*, **2014**, 6, 635-43	17.6	56
143	Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. *European Journal of Nuclear Medicine and Molecular Imaging*, **2014**, 41, 2093-105	8.8	103
142	Annotating STEAP1 regulation in prostate cancer with 89Zr immuno-PET. *Journal of Nuclear Medicine*, **2014**, 55, 2045-9	8.9	20
141	Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer. *Science Signaling*, **2014**, 7, ra29	8.8	93
140	Building Blocks for the Construction of Bioorthogonally Reactive Peptides via Solid-Phase Peptide Synthesis. *ChemistryOpen*, **2014**, 3, 48-53	2.3	21
139	Chemoenzymatic strategy for the synthesis of site-specifically labeled immunoconjugates for multimodal PET and optical imaging. *Bioconjugate Chemistry*, **2014**, 25, 2123-8	6.3	53
138	Understanding the pharmacological properties of a metabolic PET tracer in prostate cancer. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, 7254-9	11.5	34
137	Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. *Clinical Cancer Research*, **2014**, 20, 2182-91	12.9	49
136	Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: a critical analysis of patterns and outcomes. *Oral Oncology*, **2014**, 50, 45-51	4.4	63
135	Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter. *European Journal of Nuclear Medicine and Molecular Imaging*, **2014**, 41, 322-32	8.8	44
134	(89)Zr-labeled paramagnetic octreotide-liposomes for PET-MR imaging of cancer. *Pharmaceutical Research*, **2013**, 30, 878-88	4.5	71
133	Antilipolytic drug boosts glucose metabolism in prostate cancer. *Nuclear Medicine and Biology*, **2013**, 40, 524-8	2.1	3
132	Sandmeyer reaction repurposed for the site-selective, non-oxidizing radioiodination of fully-deprotected peptides: studies on the endogenous opioid peptide heoendorphin. *Bioorganic and Medicinal Chemistry Letters*, **2013**, 23, 4347-50	2.9	9
131	(18)F-labeled-bioorthogonal liposomes for in vivo targeting. *Bioconjugate Chemistry*, **2013**, 24, 1784-9	6.3	67
130	Radiopharmaceuticals for Imaging in Oncology with Special Emphasis on Positron-Emitting Agents **2013**, 35-78		2
129	PET imaging with Zr: from radiochemistry to the clinic. *Nuclear Medicine and Biology*, **2013**, 40, 3-14	2.1	268

128	Imaging tumor burden in the brain with 89Zr-transferrin. *Journal of Nuclear Medicine*, **2013**, 54, 90-5	8.9	31
127	Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET. *Journal of Nuclear Medicine*, **2013**, 54, 936-43	8.9	74
126	Enzyme-mediated methodology for the site-specific radiolabeling of antibodies based on catalyst-free click chemistry. *Bioconjugate Chemistry*, **2013**, 24, 1057-67	6.3	106
125	H(4)octapa-trastuzumab: versatile acyclic chelate system for 111In and 177Lu imaging and therapy. *Journal of the American Chemical Society*, **2013**, 135, 12707-21	16.4	68
124	Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer. *Journal of Nuclear Medicine*, **2013**, 54, 1697-702	8.9	54
123	A pretargeted PET imaging strategy based on bioorthogonal Diels-Alder click chemistry. *Journal of Nuclear Medicine*, **2013**, 54, 1389-96	8.9	213
122	The growing impact of bioorthogonal click chemistry on the development of radiopharmaceuticals. *Journal of Nuclear Medicine*, **2013**, 54, 829-32	8.9	93
121	Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology. *Journal of Nuclear Medicine*, **2013**, 54, 1876-82	8.9	48
120	Fatty acid synthase is a key target in multiple essential tumor functions of prostate cancer: uptake of radiolabeled acetate as a predictor of the targeted therapy outcome. *PLoS ONE*, **2013**, 8, e64570	3.7	78
119	Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging. *Molecular Imaging and Biology*, **2012**, 14, 25-31	3.8	10
118	Efficient (18)F-labeling of large 37-amino-acid pHLIP peptide analogues and their biological evaluation. *Bioconjugate Chemistry*, **2012**, 23, 1557-66	6.3	52
117	An improved strategy for the synthesis of [□F]-labeled arabinofuranosyl nucleosides. *Nuclear Medicine and Biology*, **2012**, 39, 1182-8	2.1	10
116	H(2)azapa: a versatile acyclic multifunctional chelator for (67)Ga, (64)Cu, (111)In, and (177)Lu. *Inorganic Chemistry*, **2012**, 51, 12575-89	5.1	45
115	Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. *Cancer Discovery*, **2012**, 2, 320-7	24.4	61
114	Annotating MYC status with 89Zr-transferrin imaging. *Nature Medicine*, **2012**, 18, 1586-91	50.5	75
113	Role of metalation in the topoisomerase II□nhibition and antiproliferation activity of a series of □heterocyclic-N4-substituted thiosemicarbazones and their Cu(II) complexes. *Journal of Medicinal Chemistry*, **2011**, 54, 2391-8	8.3	141
112	A practical guide to the construction of radiometallated bioconjugates for positron emission tomography. *Dalton Transactions*, **2011**, 40, 6168-95	4.3	144
111	The synthesis and evaluation of N1-(4-(2-[18F]-fluoroethyl)phenyl)-N8-hydroxyoctanediamide ([18F]-FESAHA), a PET radiotracer designed for the delineation of histone deacetylase expression in cancer. *Nuclear Medicine and Biology*, **2011**, 38, 683-96	2.1	14

110	The next generation of positron emission tomography radiopharmaceuticals in oncology. *Seminars in Nuclear Medicine*, **2011**, 41, 265-82	5.4	81
109	Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov Luminescence Emissions. *Molecular Imaging*, **2011**, 10, 7290.2010.00047	3.7	50
108	Intraoperative Imaging of Positron Emission Tomographic Radiotracers Using Cerenkov Luminescence Emissions. *Molecular Imaging*, **2011**, 10, 7290.2010.00047	3.7	33
107	Ex vivo sentinel lymph node mapping in laparoscopic resection of colon cancer. *Colorectal Disease*, **2011**, 13, 1249-55	2.1	7
106	Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand Diels-Alder click chemistry. *Bioconjugate Chemistry*, **2011**, 22, 2048-59	6.3	121
105	89Zr-labeled dextran nanoparticles allow in vivo macrophage imaging. *Bioconjugate Chemistry*, **2011**, 22, 2383-9	6.3	100
104	Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. *Journal of Nuclear Medicine*, **2011**, 52, 1608-15	8.9	53
103	Magnitude of enhanced permeability and retention effect in tumors with different phenotypes: 89Zr-albumin as a model system. *Journal of Nuclear Medicine*, **2011**, 52, 625-633	8.9	124
102	Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. *Nature Chemical Biology*, **2011**, 7, 818-26	11.7	208
101	Intraoperative imaging of positron emission tomographic radiotracers using Cerenkov luminescence emissions. *Molecular Imaging*, **2011**, 10, 177-86, 1-3	3.7	52
100	Imaging and treating tumor vasculature with targeted radiolabeled carbon nanotubes. *International Journal of Nanomedicine*, **2010**, 5, 783-802	7.3	97
99	Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab. *PLoS ONE*, **2010**, 5, e8859	3.7	112
98	Cerenkov luminescence imaging of medical isotopes. *Journal of Nuclear Medicine*, **2010**, 51, 1123-30	8.9	242
97	89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. *Journal of Nuclear Medicine*, **2010**, 51, 1293-300	8.9	330
96	Improved synthesis of 2Pdeoxy-2P[18F]-fluoro-1-beta-D-arabinofuranosyl-5-iodouracil ([18F]-FIAU). *Nuclear Medicine and Biology*, **2010**, 37, 439-42	2.1	30
95	Clickable bifunctional radiometal chelates for peptide labeling. *Chemical Communications*, **2010**, 46, 1706-8	5.8	40
94	Unconventional Nuclides for Radiopharmaceuticals. *Molecular Imaging*, **2010**, 9, 7290.2010.00008	3.7	108
93	Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia. *Journal of Inorganic Biochemistry*, **2010**, 104, 126-35	4.2	42

92	Unconventional nuclides for radiopharmaceuticals. *Molecular Imaging*, **2010**, 9, 1-20	3.7	44
91	In vivo biodistribution, PET imaging, and tumor accumulation of 86Y- and 111In-antimindin/RG-1, engineered antibody fragments in LNCaP tumor-bearing nude mice. *Journal of Nuclear Medicine*, **2009**, 50, 435-43	8.9	67
90	Radiopharmaceuticals in preclinical and clinical development for monitoring of therapy with PET. *Journal of Nuclear Medicine*, **2009**, 50 Suppl 1, 106S-21S	8.9	79
89	A novel technology for the imaging of acidic prostate tumors by positron emission tomography. *Cancer Research*, **2009**, 69, 4510-6	10.1	138
88	Bromination from the macroscopic level to the tracer radiochemical level: (76)Br radiolabeling of aromatic compounds via electrophilic substitution. *Bioconjugate Chemistry*, **2009**, 20, 808-16	6.3	13
87	(64)Cu-labeled CB-TE2A and diamsar-conjugated RGD peptide analogs for targeting angiogenesis: comparison of their biological activity. *Nuclear Medicine and Biology*, **2009**, 36, 277-85	2.1	84
86	Melanoma imaging using (111)In-, (86)Y- and (68)Ga-labeled CHX-AP̄Re(Arg11)CCMSH. *Nuclear Medicine and Biology*, **2009**, 36, 345-54	2.1	48
85	Standardized methods for the production of high specific-activity zirconium-89. *Nuclear Medicine and Biology*, **2009**, 36, 729-39	2.1	310
84	Functionalised copper-64 complexes as precursors of potential PET imaging agents for neurodegenerative disorders. *New Journal of Chemistry*, **2009**, 33, 1845	3.6	6
83	Synthesis and characterization of the copper(II) complexes of new N2S2-donor macrocyclic ligands: synthesis and in vivo evaluation of the (64)Cu complexes. *Dalton Transactions*, **2009**, 177-84	4.3	13
82	Copper-64 Radiopharmaceuticals for Oncologic Imaging. *PET Clinics*, **2009**, 4, 49-67	2.2	9
81	Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, **2009**, 53, 193-200	1.4	53
80	Examining the relationship between Cu-ATSM hypoxia selectivity and fatty acid synthase expression in human prostate cancer cell lines. *Nuclear Medicine and Biology*, **2008**, 35, 273-9	2.1	47
79	Evaluation of a bromine-76-labeled progestin 16alpha,17alpha-dioxolane for breast tumor imaging and radiotherapy: in vivo biodistribution and metabolic stability studies. *Nuclear Medicine and Biology*, **2008**, 35, 655-63	2.1	16
78	Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer. *Nuclear Medicine and Biology*, **2008**, 35, 713-20	2.1	74
77	An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. *Journal of Nuclear Medicine*, **2008**, 49, 1177-82	8.9	148
76	1-11C-acetate as a PET radiopharmaceutical for imaging fatty acid synthase expression in prostate cancer. *Journal of Nuclear Medicine*, **2008**, 49, 327-34	8.9	136
75	Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). *Journal of Nuclear Medicine*, **2008**, 49, 201-5	8.9	194

74	Synthesis, in vitro and in vivo characterization of (64)Cu(I) complexes derived from hydrophilic tris(hydroxymethyl)phosphane and 1,3,5-triaza-7-phosphaadamantane ligands. *Journal of Biological Inorganic Chemistry*, **2008**, 13, 307-15	3.7	42
73	Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. *Diseases of the Colon and Rectum*, **2008**, 51, 1641-8	3.1	126
72	In vitro and in vivo evaluation of bifunctional bisthiosemicarbazone 64Cu-complexes for the positron emission tomography imaging of hypoxia. *Journal of Medicinal Chemistry*, **2008**, 51, 2985-91	8.3	69
71	SU-GG-J-03: 3D Pathology Validation for Head-And-Neck Tumor Segmentation in PET/CT/MRI Images. *Medical Physics*, **2008**, 35, 2679-2679	4.4	
70	Cu-ATSM: a radiopharmaceutical for the PET imaging of hypoxia. *Dalton Transactions*, **2007**, 4893-902	4.3	186
69	Molecular imaging of gastrin-releasing peptide receptor-positive tumors in mice using 64Cu- and 86Y-DOTA-(Pro1,Tyr4)-bombesin(1-14). *Bioconjugate Chemistry*, **2007**, 18, 724-30	6.3	53
68	Imaging oxygenation of human tumours. *European Radiology*, **2007**, 17, 861-72	8	270
67	Diagnostic and prognostic value of ambulatory ECG (Holter) monitoring in patients with coronary heart disease: a review. *Journal of Thrombosis and Thrombolysis*, **2007**, 23, 135-45	5.1	24
66	NuMA influences higher order chromatin organization in human mammary epithelium. *Molecular Biology of the Cell*, **2007**, 18, 348-61	3.5	56
65	In vivo imaging in a murine model of glioblastoma. *Neurosurgery*, **2007**, 60, 360-70; discussion 370-1	3.2	34
64	Gallium-68-labeled DOTA-rhenium-cyclized alpha-melanocyte-stimulating hormone analog for imaging of malignant melanoma. *Nuclear Medicine and Biology*, **2007**, 34, 945-53	2.1	43
63	An anatomical study of tibial metaphyseal/diaphyseal mismatch during revision total knee arthroplasty. *Journal of Arthroplasty*, **2007**, 22, 241-4	4.4	22
62	Radiometal-labeled somatostatin analogs for applications in cancer imaging and therapy. *Methods in Molecular Biology*, **2007**, 386, 227-40	1.4	16
61	Production of non-standard PET radionuclides and the application of radiopharmaceuticals labeled with these nuclides. *Ernst Schering Research Foundation Workshop*, **2007**, 159-81		13
60	Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. *Journal of Nuclear Medicine*, **2007**, 48, 64-72	8.9	56
59	Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. *International Journal of Radiation Biology*, **2006**, 82, 699-757	2.9	506
58	Validation of a novel CHX-A‴derivative suitable for peptide conjugation: small animal PET/CT imaging using yttrium-86-CHX-A‴octreotide. *Journal of Medicinal Chemistry*, **2006**, 49, 4297-304	8.3	45
57	In vivo skeletal imaging of 18F-fluoride with positron emission tomography reveals damage- and time-dependent responses to fatigue loading in the rat ulna. *Bone*, **2006**, 39, 229-36	4.7	42

56	Three-dimensional maximum a posteriori (MAP) imaging with radiopharmaceuticals labeled with three Cu radionuclides. *Nuclear Medicine and Biology*, **2006**, 33, 217-26	2.1	33
55	64Cu-azabicyclo[3.2.2]nonane thiosemicarbazone complexes: radiopharmaceuticals for PET of topoisomerase II expression in tumors. *Journal of Nuclear Medicine*, **2006**, 47, 2034-41	8.9	20
54	Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH. *Journal of Medicinal Chemistry*, **2005**, 48, 2985-92	8.3	109
53	Basic characterization of 64Cu-ATSM as a radiotherapy agent. *Nuclear Medicine and Biology*, **2005**, 32, 21-8	2.1	85
52	Investigation into 64Cu-labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents. *Nuclear Medicine and Biology*, **2005**, 32, 147-56	2.1	64
51	Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM. *Nuclear Medicine and Biology*, **2005**, 32, 623-30	2.1	86
50	Preparation of high specific activity (86)Y using a small biomedical cyclotron. *Nuclear Medicine and Biology*, **2005**, 32, 891-7	2.1	75
49	Measurement of input functions in rodents: challenges and solutions. *Nuclear Medicine and Biology*, **2005**, 32, 679-85	2.1	88
48	Radiolabeled Antibodies for Tumor Imaging and Therapy **2005**, 685-714		
47	Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. *International Journal of Radiation Oncology Biology Physics*, **2005**, 61, 1493-502	4	163
46	A tat fusion protein-based tumor vaccine for breast cancer. *Annals of Surgical Oncology*, **2005**, 12, 517-25	3.1	24
45	Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET. *European Journal of Nuclear Medicine and Molecular Imaging*, **2005**, 32, 764-70	8.8	60
44	Positron-emitting isotopes produced on biomedical cyclotrons. *Current Medicinal Chemistry*, **2005**, 12, 807-18	4.3	56
43	Identification of a novel prostate tumor target, mindin/RG-1, for antibody-based radiotherapy of prostate cancer. *Cancer Research*, **2005**, 65, 8397-405	10.1	40
42	In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. *European Journal of Nuclear Medicine and Molecular Imaging*, **2003**, 30, 844-50	8.8	314
41	Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. *International Journal of Radiation Oncology Biology Physics*, **2003**, 55, 1233-8	4	295
40	Polyclonal antibodies to xenogeneic endothelial cells induce apoptosis and block support of tumor growth in mice. *Vaccine*, **2003**, 21, 2667-77	4.1	11
39	Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG. *Nuclear Medicine and Biology*, **2003**, 30, 529-34	2.1	49

38	Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals. *Nuclear Medicine and Biology*, **2003**, 30, 725-31	2.1	102
37	Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose. *Cancer Research*, **2003**, 63, 5496-504	10.1	41
36	Molecular imaging: the application of small animal positron emission tomography. *Journal of Cellular Biochemistry*, **2002**, 39, 110-5	4.7	28
35	Copper bis(thiosemicarbazone) complexes as hypoxia imaging agents: structure-activity relationships. *Journal of Biological Inorganic Chemistry*, **2002**, 7, 249-59	3.7	217
34	DOTA-D-Tyr(1)-octreotate: a somatostatin analogue for labeling with metal and halogen radionuclides for cancer imaging and therapy. *Bioconjugate Chemistry*, **2002**, 13, 721-8	6.3	65
33	Small animal imaging. current technology and perspectives for oncological imaging. *European Journal of Cancer*, **2002**, 38, 2173-88	7.5	141
32	Copper-64-pyruvaldehyde-bis(N(4)-methylthiosemicarbazone) for the prevention of tumor growth at wound sites following laparoscopic surgery: monitoring therapy response with microPET and magnetic resonance imaging. *Cancer Research*, **2002**, 62, 445-9	10.1	25
31	Delineation of hypoxia in canine myocardium using PET and copper(II)-diacetyl-bis(N(4)-methylthiosemicarbazone). *Journal of Nuclear Medicine*, **2002**, 43, 1557-69	8.9	69
30	Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. *Annals of Nuclear Medicine*, **2001**, 15, 499-504	2.5	114
29	A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. *International Journal of Radiation Oncology Biology Physics*, **2001**, 49, 1171-82	4	365
28	Toxicity and dosimetry of (177)Lu-DOTA-Y3-octreotate in a rat model. *International Journal of Cancer*, **2001**, 94, 873-7	7.5	48
27	64Cu-PTSM as an inhibitor of tumor recurrence. *Journal of Labelled Compounds and Radiopharmaceuticals*, **2001**, 44, S87-S89	1.9	
26	Copper-64/61 and iodine-125-labeled dota-DTYR1-octreotate: A new somatostatin analog for labeling with metals and halogens. *Journal of Labelled Compounds and Radiopharmaceuticals*, **2001**, 44, S948-S950	1.9	2
25	Copper-64-diacetyl-bis(N4-methylthiosemicarbazone): An agent for radiotherapy. *Proceedings of the National Academy of Sciences of the United States of America*, **2001**, 98, 1206-11	11.5	164
24	64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. *Journal of Nuclear Medicine*, **2001**, 42, 213-21	8.9	194
23	Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation. *Journal of Nuclear Medicine*, **2001**, 42, 655-61	8.9	130
22	PET imaging of hypoxia. *The Quarterly Journal of Nuclear Medicine: Official Publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)*, **2001**, 45, 183-8		16
21	Copper bis(diphosphine) complexes: radiopharmaceuticals for the detection of multi-drug resistance in tumours by PET. *European Journal of Nuclear Medicine and Molecular Imaging*, **2000**, 27, 638-46	8.8	33

20	Comparative dosimetry of copper-64 and yttrium-90-labeled somatostatin analogs in a tumor-bearing rat model. *Cancer Biotherapy and Radiopharmaceuticals*, **2000**, 15, 593-604	3.9	22
19	Radiopharmaceuticals for targeted radiotherapy of cancer. *Expert Opinion on Therapeutic Patents*, **2000**, 10, 1057-1069	6.8	16
18	Metal complexes as diagnostic tools. *Coordination Chemistry Reviews*, **1999**, 184, 3-66	23.2	218
17	Utilization of metabolic, transport and receptor-mediated processes to deliver agents for cancer diagnosis. *Advanced Drug Delivery Reviews*, **1999**, 37, 189-211	18.5	18
16	In vitro and in vivo evaluation of 64Cu-TETA-Tyr3-octreotate. A new somatostatin analog with improved target tissue uptake. *Nuclear Medicine and Biology*, **1999**, 26, 267-73	2.1	81
15	High purity production and potential applications of copper-60 and copper-61. *Nuclear Medicine and Biology*, **1999**, 26, 351-8	2.1	120
14	Comparison of four 64Cu-labeled somatostatin analogues in vitro and in a tumor-bearing rat model: evaluation of new derivatives for positron emission tomography imaging and targeted radiotherapy. *Journal of Medicinal Chemistry*, **1999**, 42, 1341-7	8.3	86
13	Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model. *Journal of Nuclear Medicine*, **1999**, 40, 177-83	8.9	230
12	Radiotherapy and dosimetry of 64Cu-TETA-Tyr3-octreotate in a somatostatin receptor-positive, tumor-bearing rat model. *Clinical Cancer Research*, **1999**, 5, 3608-16	12.9	66
11	Design of hypoxia-targeting radiopharmaceuticals: selective uptake of copper-64 complexes in hypoxic cells in vitro. *European Journal of Nuclear Medicine and Molecular Imaging*, **1998**, 25, 788-92	8.8	84
10	Effect of ligand and solvent on chloride ion coordination in anti-tumour copper(I) diphosphine complexes: Synthesis of [Cu(dppe)2]Cl and analogous complexes (dppe = 1,2-bis(diphenylphosphino)ethane). *Polyhedron*, **1998**, 17, 513-517	2.7	19
9	Radiotherapy, toxicity and dosimetry of copper-64-TETA-octreotide in tumor-bearing rats. *Journal of Nuclear Medicine*, **1998**, 39, 1944-51	8.9	85
8	Diphosphine bifunctional chelators for low-valent metal ions. Crystalstructures of the copper(I) complexes [CuClL12]and [CuL12][PF6][L1 = 2,3-bis(diphenylphosphino)maleicanhydride]. *Journal of the Chemical Society Dalton Transactions*, **1997**, 855-862		18
7	Copper radionuclides and radiopharmaceuticals in nuclear medicine. *Nuclear Medicine and Biology*, **1996**, 23, 957-80	2.1	321
6	Copper(I) bis(diphosphine) complexes as a basis for radiopharmaceuticals for positron emission tomography and targeted radiotherapy. *Chemical Communications*, **1996**, 1093	5.8	26
5	Rhenium complex of a triply deprotonated chelated thiosemicarbazide and its conversion to a nitride complex via a hydrazide intermediate. Crystal structure of [ReCl2(NH)(NHNH2)(PPh3)2]. *Journal of the Chemical Society Dalton Transactions*, **1995**, 1357		18
4	The preparation of rhenium(V) oxo and imido complexes with Et2NCSNHCOPh and Et2NCSBC(NH)Ph. The x-ray crystal structure of [ReOCl(PhCONCSNEt2)2]. *Polyhedron*, **1993**, 12, 221-225	2.7	14
3	PARP1/2 imaging with 18F-PARPi in patients with head and neck cancer		2

2 A simple strategy to reduce the salivary gland and kidney uptake of PSMA targeting small molecule radiopharmaceuticals 1

1 Targeted brain tumor radiotherapy using an Auger emitter 2